Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00045916 · ClinicalTrials.gov registry record · Phase 4

Optimizing Electroconvulsive Therapy for Depression

A Phase 4 study of Depression and Bipolar Disorder, sponsored by New York State Psychiatric Institute.

Completed
Registry status
Phase 4
Development phase
340
Enrollment target
4
Study locations

NCT00045916: Completed Phase 4 study of Depression and Bipolar Disorder, sponsored by New York State Psychiatric Institute.

NCT00045916 is a Phase 4 study of Depression and Bipolar Disorder that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 340 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (57% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00045916, a Phase 4 study of Depression and Bipolar Disorder, has completed, sponsored by New York State Psychiatric Institute.

COMPLETED
Registry status
Phase 4
Development phase
340 participants
Enrollment target
4
Study locations

Study Summary

This study will evaluate the effectiveness of electroconvulsive therapy (ECT) administered with medication for the treatment of a major depressive episode (unipolar or bipolar) and will compare two types of ECT.

Interventions

  • DRUG Lithium
  • DRUG Nortriptyline
  • DRUG Venlafaxine
  • PROCEDURE High dosage electroconvulsive therapy
  • PROCEDURE Low dosage electroconvulsive therapy

Study Locations (4)

Missouri

  • Washington University - St Louis

New York

  • New York State Psychiatric Institute at Columbia University - New York

North Carolina

  • Wake Forest University - Winston-Salem

Pennsylvania

  • Western Psychiatric Institute and Clinic - Pittsburgh

Trial Details

FieldValue
Enrollment Target 340 participants
Start Date 2001-02
Est. Completion 2006-12
Phase Phase 4

What the finished NCT00045916 record still lists

NCT00045916 is an interventional study that assigns participants to a tested intervention. The registered 340 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (57% lower).

The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 5 interventions - of which Lithium is the first listed.

NCT00045916 reports a single indexed study location in Missouri, New York, North Carolina.

Frequently Asked Questions

What is clinical trial NCT00045916 about?

NCT00045916 is a clinical study titled "Optimizing Electroconvulsive Therapy for Depression". This study will evaluate the effectiveness of electroconvulsive therapy (ECT) administered with medication for the treatment of a major depressive episode (unipolar or bipolar) and will compare two types of ECT.

What is the current status of trial NCT00045916?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 340 participants. The study started on 2001-02. Estimated completion is 2006-12.

What conditions does trial NCT00045916 study?

This clinical trial studies the following conditions: Depression, Bipolar Disorder, Depressive Disorder.

What interventions are being tested in trial NCT00045916?

The interventions under investigation include: Lithium (DRUG), Nortriptyline (DRUG), Venlafaxine (DRUG), High dosage electroconvulsive therapy (PROCEDURE), Low dosage electroconvulsive therapy (PROCEDURE).

Who is sponsoring clinical trial NCT00045916?

This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00045916 being conducted?

This trial has 4 study locations across Missouri, New York, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00045916's enrollment target sits among peer trials

340 126th of 679 higher than 553 of 679 other Depression trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04176172 · 340 participants · Phase 3

    Optimizing Tobacco Use Treatment for PLWHA

  • NCT04545424 · 340 participants · Phase 2

    Trial of Therapeutic Hypothermia in Patients With ARDS

  • NCT04806958 · 340 participants · NA

    The PulsePoint Study

  • NCT05323409 · 340 participants · NA

    Improving Comprehensive Care of Cancer Patients

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00045916, the US trial registry maintained by the National Library of Medicine. NCT00045916 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.